Belada, David ORCID: 0000-0002-4981-6188, Georgiev, Pencho ORCID: 0000-0001-5677-6754, Dakhil, Shaker, Inhorn, Lowell F., Andorsky, David, Beck, J. Thaddeus, Quick, Donald, Pettengell, Ruth, Daly, Robert, Dean, James P., Pavlyuk, Mariya, Failloux, Nelly and Huebel, Kai (2016). Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. Future Oncol., 12 (15). S. 1759 - 1769. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Full text not available from this repository.

Abstract

We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma, who are ineligible for high-dose chemotherapy and stem cell transplantation, and who failed front-line regimens containing rituximab. The administration schedule is pixantrone 50 mg/m(2) intravenously (iv.) or gemcitabine 1000 mg/m(2) iv. on days 1, 8 and 15, combined with rituximab 375 mg/m(2) iv. on day 1, up to six cycles. Pixantrone has a conditional European marketing approval for monotherapy in adults with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Our trial explores the efficacy of combining pixantrone with rituximab and completes postauthorization measures. Trial registration number: NCT01321541.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Belada, DavidUNSPECIFIEDorcid.org/0000-0002-4981-6188UNSPECIFIED
Georgiev, PenchoUNSPECIFIEDorcid.org/0000-0001-5677-6754UNSPECIFIED
Dakhil, ShakerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Inhorn, Lowell F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Andorsky, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beck, J. ThaddeusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Quick, DonaldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pettengell, RuthUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Daly, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dean, James P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pavlyuk, MariyaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Failloux, NellyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huebel, KaiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-268839
DOI: 10.2217/fon-2016-0137
Journal or Publication Title: Future Oncol.
Volume: 12
Number: 15
Page Range: S. 1759 - 1769
Date: 2016
Publisher: FUTURE MEDICINE LTD
Place of Publication: LONDON
ISSN: 1744-8301
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
B-CELL LYMPHOMA; MULTICENTER PHASE-II; SINGLE-AGENT; MALIGNANT-LYMPHOMA; ADULT PATIENTS; REGIMENS; TRIAL; DRUG; CHOPMultiple languages
OncologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/26883

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item